.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Harvard Business School
US Department of Justice
Fish and Richardson
Chubb
Argus Health
Merck
Novartis
Citi
Moodys

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091166

« Back to Dashboard
NDA 091166 describes ESZOPICLONE, which is a drug marketed by Sun Pharma Global, Orchid Hlthcare, Dr Reddys Labs Ltd, Lupin Ltd, Macleods Pharms Ltd, Aurobindo Pharma Ltd, Mylan Pharms Inc, West-ward Pharms Int, Wockhardt Ltd, Glenmark Generics, and Teva, and is included in eleven NDAs. It is available from thirty suppliers. Additional details are available on the ESZOPICLONE profile page.

The generic ingredient in ESZOPICLONE is eszopiclone. There are twenty drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the eszopiclone profile page.

Summary for 091166

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Sedatives/Hypnotics
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 091166

Suppliers and Packaging for NDA: 091166

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ESZOPICLONE
eszopiclone
TABLET;ORAL 091166 ANDA Aidarex Pharmaceuticals LLC 53217-150 53217-150-30 30 TABLET, FILM COATED in 1 BOTTLE (53217-150-30)
ESZOPICLONE
eszopiclone
TABLET;ORAL 091166 ANDA DirectRX 61919-991 61919-991-90 90 TABLET, FILM COATED in 1 BOTTLE (61919-991-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Apr 15, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Apr 15, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength3MG
Approval Date:Apr 15, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Argus Health
Dow
AstraZeneca
US Department of Justice
Express Scripts
Chubb
Cipla
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot